Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2019 - 2023)

Historic Net Income towards Common Stockholders for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$47807.0.

  • ADC Therapeutics' Net Income towards Common Stockholders fell 10009.45% to -$47807.0 in Q3 2023 from the same period last year, while for Dec 2023 it was -$154350.0, marking a year-over-year decrease of 10011.73%. This contributed to the annual value of -$155800.0 for FY2022, which is 9993.04% up from last year.
  • ADC Therapeutics' Net Income towards Common Stockholders amounted to -$47807.0 in Q3 2023, which was down 10009.45% from -$47117.0 recorded in Q2 2023.
  • ADC Therapeutics' 5-year Net Income towards Common Stockholders high stood at $126.6 million for Q2 2020, and its period low was -$59426.0 during Q1 2023.
  • Its 5-year average for Net Income towards Common Stockholders is $32.3 million, with a median of $18.5 million in 2020.
  • In the last 5 years, ADC Therapeutics' Net Income towards Common Stockholders soared by 54214642.8% in 2020 and then plummeted by 10035.67% in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' Net Income towards Common Stockholders stood at -$35285.0 in 2019, then surged by 57710.88% to $20.3 million in 2020, then surged by 251.97% to $71.5 million in 2021, then plummeted by 100.03% to -$24157.0 in 2022, then plummeted by 97.9% to -$47807.0 in 2023.
  • Its Net Income towards Common Stockholders stands at -$47807.0 for Q3 2023, versus -$47117.0 for Q2 2023 and -$59426.0 for Q1 2023.